TITLE

A case of non-Hodgkin’s lymphoma primary arising in both adrenal glands associated with adrenal failure

AUTHOR(S)
Takamasa Nishiuchi; Hitomi Imachi; Mako Fujiwara; Koji Murao; Hiroaki Onishi; Tohru Kiguchi; Hidetaka Takimoto; Yoshio Kushida; Reiji Haba; Toshihiko Ishida
PUB. DATE
February 2009
SOURCE
Endocrine (1355008X);Feb2009, Vol. 35 Issue 1, p34
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract  It is known that adrenal insufficiency is one of the complications in primary adrenal lymphoma, especially those with bilateral adrenal involvement. A 73-year-old man was referred for general fatigue and high fever to the nearest hospital. The patient was transferred to our hospital for evaluation of bilateral adrenal tumors and hyponatremia. He was diagnosed as having non-Hodgkin’s lymphoma (NHL) with primaries arising in both adrenal glands. Primary adrenal lymphoma (PAL) is a rare extra-nodal NHL. Although an appropriate treatment of this disease has not been established, our case has demonstrated that the combination of rituximab and THP-COP chemotherapy could be administered, and that it improved clinical manifestations. This case raises the suggestion that malignant lymphoma should be suspected in patients with bilateral adrenal tumors that present with progressive adrenal insufficiency.
ACCESSION #
36177717

 

Related Articles

  • Novel Therapies for Aggressive B-Cell Lymphoma. Foon, Kenneth A.; Takeshita, Kenichi; Zinzani, Pier L. // Advances in Hematology;2012, p1 

    Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lymphoma. Advances in chemoimmunotherapy have substantially...

  • Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. Xue, Kai; Gu, Juan; Zhang, Qunling; Mavis, Cory; Hernandez-Ilizaliturri, Francisco; Czuczman, Myron; Guo, Ye // Journal of Cancer Research & Clinical Oncology;Feb2016, Vol. 142 Issue 2, p379 

    Purpose: Preclinical models of chemotherapy resistance and clinical observations derived from the prospective multicenter phase III collaborative trial in relapsed aggressive lymphoma (CORAL) study demonstrated that primary refractory/relapsed B cell diffuse large B cell lymphoma has a poor...

  • O-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. Jiang, Xiaoyin; Reardon, David; Desjardins, Annick; Vredenburgh, James; Quinn, Jennifer; Austin, Alan; Herndon, James; McLendon, Roger; Friedman, Henry // Journal of Neuro-Oncology;Aug2013, Vol. 114 Issue 1, p135 

    Temozolomide, an alkylating agent, has shown promise in treating primary central nervous system lymphoma (PCNSL). The enzyme O-methylguanine-DNA methyltransferase (MGMT) repairs alkylating damage, such as that induced by temozolomide. We hypothesized that MGMT immunohistochemistry would predict...

  • Primary chest wall lymphoma: A rare entity. Shah, Binay Kumar // Journal of Cancer Research & Therapeutics;Jul-Sep2015, Vol. 11 Issue 3, Special section p661 

    Primary chest wall lymphoma is a rare but curable condition. This paper reports a case of a 52-year-old female patient who presented with a primary chest wall diffuse large B-cell lymphoma.

  • Treatment of Skin Tumors with Electrochemotherapy. Asilian, Ali; Momeni, Iman; Basiri, Akram // Journal of Isfahan Medical School;Apr2013, Vol. 31 Issue 226, p180 

    Electrochemotherapy involves the application of chemotherapy followed by local electrical pulse around the tumor to increase drug delivery into tumor cells. Electroporation is used to increase drug absorbance only for medications whose transport is prevented by plasma membrane. Among all...

  • New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Ocio, E M; Richardson, P G; Rajkumar, S V; Palumbo, A; Mateos, M V; Orlowski, R; Kumar, S; Usmani, S; Roodman, D; Niesvizky, R; Einsele, H; Anderson, K C; Dimopoulos, M A; Avet-Loiseau, H; Mellqvist, U-H; Turesson, I; Merlini, G; Schots, R; McCarthy, P; Bergsagel, L // Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p525 

    Treatment in medical oncology is gradually shifting from the use of nonspecific chemotherapeutic agents toward an era of novel targeted therapy in which drugs and their combinations target specific aspects of the biology of tumor cells. Multiple myeloma (MM) has become one of the best examples...

  • Nem tudo o que brilha é câncer: criptococose pulmonar mimetizando linfoma na tomografia por emissão de pósitrons com [(18)] F fluoro-2-desoxi-D-glicose. Hamerschlak, Nelson; Pasternak, Jacyr; Wagner, Jairo; Fleury Perini, Guilherme // Einstein (16794508);Oct2012, Vol. 10 Issue 4, p502 

    We report of a case of pulmonary cryptococcosis mimicking lymphoma in a positron emission tomography (FDG-PET) scan. A 62-year old man with diffuse large B-cell lymphoma had complete resolution of abdominal and pulmonary lesions after three cycles of rituximab-based chemotherapy (R-CHOP)....

  • Bendamustine Outperforms R-CHOP in NHL.  // American Health & Drug Benefits;August Special Issue 2012, Vol. 5, p24 

    The article discusses a 2012 meeting of the American Society of Clinical Oncology in Chicago, Illinois, focusing on a report from the doctor Mathias J. Rummel concerning the StiL NHL1 clinical trial in which the treatment of non-Hodgkin lymphoma with bendamustine and rituximab was investigated.

  • It's a targeted world in non-Hodgkin's lymphoma. Okosun, Jessica; Fitzgibbon, Jude // British Journal of Nursing;9/22/2011 Supplement, pS28 

    In this article the authors discuss targeted therapies which are used in the treatment of non-Hodgkin's lymphoma. They are supportive of the use of targeted therapies in cancer patients and of research which is being conducted and may be conducted in the future on tumors and which may lead to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics